

PRODUCT INFORMATION

Clone ID	19A5
Target	FLT3
Synonyms	Flt-3;Flk-2;STK-1;CD135;FLK2;FLT-3
Host Species	Rabbit
Description	Biotinylated Anti-FLT3 antibody(19A5), IgG1 Chimeric mAb
Delivery	2-3 weeks
Uniprot ID	P36888
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1/100
Purification	Purified from cell culture supernatant by affinity chromatography
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	Flt-3(Receptor-type tyrosine-protein kinase FLT3) is also known as FLK-2(Fetal liver kinase-2), STK-1(Stem cell tyrosine kinase 1), CD135. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scr



DIMABIO CONFIDENTIAL

